TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30296300

Group type: EXPERIMENTAL
Intervention: Improved cookstove system using sustainably produced biomass pellets and fan micro-gasification stove
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-adoption of improved cookstove system
Number of subjects: 48
Study: 27926630

Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with dexmedetomidine
Number of subjects: 4
Study: 25269777

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg via a single, subcutaneous, 1-mL injection every 2 weeks (Q2W) as add-on therapy to atorvastatin or rosuvastatin
Number of subjects: 650

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/d as add-on therapy to statin
Number of subjects: 650

Group type: COMPARATOR
Intervention: Statin up-titration
Number of subjects: 650

Group type: COMPARATOR
Intervention: Switch from atorvastatin to rosuvastatin
Number of subjects: 650
Study: 22313193

Group type: EXPERIMENTAL
Intervention: Nitinol stents
Number of subjects: 206

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 206
Study: 20851310

Group type: EXPERIMENTAL
Intervention: Whey protein with low content of minerals
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Whey protein with high content of minerals
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Casein protein with low content of minerals
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Casein protein with high content of minerals
Number of subjects: 57
Study: 17174082

Group type: EXPERIMENTAL
Intervention: high-frequency neuromuscular electrical stimulation (hf-NMES) at 50Hz for 6 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: high-frequency neuromuscular electrical stimulation (hf-NMES)
Number of subjects: 17
Study: 15515655

Group type: EXPERIMENTAL
Intervention: Intravenous furosemid administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 20
Study: 11172139

Group type: EXPERIMENTAL
Intervention: Peripheral-blood cells mobilized with filgrastim
Number of subjects: 172

Group type: COMPARATOR
Intervention: Bone marrow
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Peripheral-blood cells
Number of subjects: 172
Study: 9753069

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (alloBMT)
Number of subjects: 831

Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 831
Study: 7921322

Group type: EXPERIMENTAL
Intervention: Variation in invitation letters
Number of subjects: 3874

Group type: EXPERIMENTAL
Intervention: Use of a brochure with the recruitment mailing
Number of subjects: 3874

Group type: EXPERIMENTAL
Intervention: Options for interview location
Number of subjects: 3874

Group type: EXPERIMENTAL
Intervention: Age (60 to 74 years)
Number of subjects: 3874

Group type: EXPERIMENTAL
Intervention: Home location (rural vs. Rochester city)
Number of subjects: 3874
Study: 3281058

Group type: EXPERIMENTAL
Intervention: Diltiazem (8 mg/kg/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31728632

Group type: EXPERIMENTAL
Intervention: 80 mg aerosol furosemide
Number of subjects: 15

Group type: COMPARATOR
Intervention: aerosol saline
Number of subjects: 15
Study: 30773358

Group type: EXPERIMENTAL
Intervention: First constrained liner
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Second constrained liner
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Third constrained liner
Number of subjects: 554
Study: 28051969

Group type: EXPERIMENTAL
Intervention: TMARP plus NMES (n = 23)
Number of subjects: 44

Group type: COMPARATOR
Intervention: TMARP alone (n = 21)
Number of subjects: 44
Study: 25027030

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 0
Study: 24011687

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 108

Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 108
Study: 20729007

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) within 77 days after BCS
Number of subjects: 964

Group type: COMPARATOR
Intervention: Radiotherapy (RT) after 77 days
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) within 48 days
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) between 49-77 days
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) between 78-112 days
Number of subjects: 964
Study: 19450288

Group type: EXPERIMENTAL
Intervention: Active video game upgrade package
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 330
Study: 16306801

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily for 4 weeks
Number of subjects: 20
Study: 11943969

Group type: EXPERIMENTAL
Intervention: Problem-solving skills training (PSST)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard psychosocial care (Control Group)
Number of subjects: 92
Study: 9616531

Group type: EXPERIMENTAL
Intervention: EIB test (submaximal treadmill run)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: CA-EIB test (submaximal treadmill run while inhaling cold air -20 degrees C)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Metacholine inhalation test
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: EIB test
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: CA-EIB test
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Metacholine provocation test
Number of subjects: 58
Study: 7630692

Group type: EXPERIMENTAL
Intervention: 15 mg of MPH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg of MPH
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MPH (both doses)
Number of subjects: 12
Study: 320809

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 26
Study: 31374471

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive behavioral therapy (CBT) program (UPLIFT, n = 20)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Epilepsy information and self-management program (EpINFO, n = 24)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Wait-list control (WLC, n = 11)
Number of subjects: 55
Study: 28002229

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (group US)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Palpation (group Palp)
Number of subjects: 70
Study: 25823738

Group type: EXPERIMENTAL
Intervention: Vitamin D deficient (< 20 ng/mL) in SWOG cohort
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin D deficient (< 10 ng/mL) in LYSA cohort
Number of subjects: 100
Study: 23555035

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) for mothers and infants, initiated at 14 weeks of pregnancy
Number of subjects: 217

Group type: COMPARATOR
Intervention: Antiretroviral therapy (ART) for mothers and infants, initiated at 28 weeks of pregnancy (prior PMTCT recommendations)
Number of subjects: 217
Study: 21546222

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 19275278

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (3 mg/kg/day)
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Micafungin
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Liposomal amphotericin B (10 mg/kg/day)
Number of subjects: 1095
Study: 17067452

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) transplantation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dental implant therapy alone (Control)
Number of subjects: 50
Study: 15037413

Group type: EXPERIMENTAL
Intervention: High Protein Diet (HP: 30% protein, 40% carbohydrate, 30% fat)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High Carbohydrate Diet (HC: 15% protein, 55% carbohydrate, 30% fat)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Both diets (HP and HC)
Number of subjects: 35
Study: 11323580

Group type: EXPERIMENTAL
Intervention: Sequential ligation-sclerotherapy (SLS)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL) alone
Number of subjects: 86
Study: 9135361

Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2.5 micrograms kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study: 7965279

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg once a day
Number of subjects: 146

Group type: COMPARATOR
Intervention: Captopril 100 mg twice a day
Number of subjects: 146
Study: 3604959

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 3% NaBr solution (1 cc per kg body weight)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oral administration of 3% NaBr solution (3 times over 6 weeks)
Number of subjects: 7
Study: 29844496

Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 39

Group type: COMPARATOR
Intervention: MDMA
Number of subjects: 39
Study: 26071431

Group type: EXPERIMENTAL
Intervention: Pilot study with large numbers of clusters and individual participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot studies
Number of subjects: 0
Study: 24599111

Group type: EXPERIMENTAL
Intervention: Structured personal care
Number of subjects: 1381

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1381
Study: 23782932

Group type: EXPERIMENTAL
Intervention: Embrace (integrated elderly care model)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study: 20724711

Group type: EXPERIMENTAL
Intervention: Hypothermia (endovascular cooling to 33°C for 24 hours followed by 12 hours of controlled rewarming)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normothermia (standard treatment)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 59
Study: 19008675

Group type: EXPERIMENTAL
Intervention: AERO+ST (Aerobic combined with strength training)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: AERO+RA (Aerobic combined with recreational activities)
Number of subjects: 33
Study: 15965989

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 12376472

Group type: EXPERIMENTAL
Intervention: Aromatic/hydrophobic-DNA adducts in white blood cells (WBC)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Combined GSTM1 null/GSTP1 Val genotype
Number of subjects: 262

Group type: COMPARATOR
Intervention: GSTM1 non-null/GSTP1 Ile genotype
Number of subjects: 262
Study: 10369626

Group type: EXPERIMENTAL
Intervention: Antiretroviral agents (stavudine, lamivudine, saquinavir soft-gel capsules, nelfinavir, efavirenz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azithromycin, cidofovir, famciclovir, valacyclovir, itraconazole suspension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liposomal-based amphotericin products
Number of subjects: 0
Study: 7771038

Group type: EXPERIMENTAL
Intervention: Automated thermo-infusion dispenser with trental and actovegin for 120-hour infusion therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (traditional methods)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Group 2 (not specified intervention)
Number of subjects: 21
Study: 2181951

Group type: EXPERIMENTAL
Intervention: High-frequency ventilation (HFV)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 113
Study: 379112

Group type: EXPERIMENTAL
Intervention: Accommodative training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceptual-motor training (Control)
Number of subjects: 0
Study: 31971403

Group type: EXPERIMENTAL
Intervention: Intervention group (IG, treating team received PAT summary)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (CG, no summary)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Patients and siblings
Number of subjects: 122
Study: 30609983

Group type: EXPERIMENTAL
Intervention: Mobile phone-based telemedicine system with glucometers and advice on medication, diet, and exercise
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Mobile phone-based telemedicine system
Number of subjects: 91

Group type: COMPARATOR
Intervention: Routine outpatient care (Control)
Number of subjects: 91
Study: 28071654

Group type: EXPERIMENTAL
Intervention: SES‐CD
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: CDEIS
Number of subjects: 112
Study: 25700323

Group type: EXPERIMENTAL
Intervention: 0.1% fluorometholone (FML) and 0.1% sodium hyaluronate (HA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% cyclosporin A (CsA) and 0.1% HA
Number of subjects: 40
Study: 23932438

Group type: EXPERIMENTAL
Intervention: FDC solifenacin 6 mg plus TOCAS 0.4 mg
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: FDC solifenacin 9 mg plus TOCAS 0.4 mg
Number of subjects: 1334

Group type: COMPARATOR
Intervention: TOCAS 0.4 mg
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1334
Study: 22372283

Group type: EXPERIMENTAL
Intervention: Six-day course providing training in communication, emotional and spiritual support, and personal introspection on death anxiety.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group of HCWs who cared for dying patients in settings other than palliative care units.
Number of subjects: 150
Study: 19255379

Group type: EXPERIMENTAL
Intervention: Preventive stepped-care program (n = 86)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care (n = 84)
Number of subjects: 170
Study: 16703972

Group type: EXPERIMENTAL
Intervention: Random urine drug testing
Number of subjects: 500

Group type: COMPARATOR
Intervention: Previous data comparison
Number of subjects: 500

Group type: COMPARATOR
Intervention: Elderly patients
Number of subjects: 500
Study: 15596188

Group type: EXPERIMENTAL
Intervention: Cooled TUMT at approximately 55 degrees C
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cooled TUMT at approximately 70 degrees C
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cooled TUMT
Number of subjects: 42
Study: 11306519

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 22
Study: 10759688

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8829019

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily (increased to 400 mg twice daily if no improvement after 72 hours)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole 960 mg twice daily
Number of subjects: 162
Study: 1601317

Group type: EXPERIMENTAL
Intervention: Intracervical enprostil
Number of subjects: 188

Group type: COMPARATOR
Intervention: Oxytocin (control group)
Number of subjects: 188
Study: 4046609

Group type: EXPERIMENTAL
Intervention: 3000 micrograms dihydrotestosterone (DHT) infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3000 micrograms estradiol (E2) infusion
Number of subjects: 0
Study: 29795532

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) plus penile ring block (PRB) with bupivacaine injection
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) plus penile ring block (PRB) with ropivacaine injection
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group without DPNB or PRB injection
Number of subjects: 131
Study: 26739146

Group type: EXPERIMENTAL
Intervention: Vein bypass surgery
Number of subjects: 600

Group type: COMPARATOR
Intervention: Best endovascular treatment (angioplasty or stenting)
Number of subjects: 600
Study: 24667938

Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 22409379

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy in older patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Induction chemotherapy in younger patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Infections during induction in older patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Infections during induction in younger patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Drug reductions in older patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Drug reductions in younger patients
Number of subjects: 100
Study: 19958075

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 or 300 mg/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 or 300 mg/day)
Number of subjects: 88
Study: 17907102

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil/hydrochlorothiazide (CC/HCTZ), 16 mg plus 12.5 mg
Number of subjects: 203

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 203
Study: 16076985

Group type: EXPERIMENTAL
Intervention: Troglitazone treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 72
Study: 12118868

Group type: EXPERIMENTAL
Intervention: Control-display mapping with vertical and depth dimensions coupled to up-down and fore-aft control axes
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tracking along the depth dimension
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tracking along the up-down axis of the hand controller
Number of subjects: 16
Study: 10450339

Group type: EXPERIMENTAL
Intervention: Clonazepam treatment for 10 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Compressed gas (atmospheric air)
Number of subjects: 6
Study: 7799087

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide
Number of subjects: 24
Study: 2135706

Group type: EXPERIMENTAL
Intervention: Nimodipine 30-60 mg orally 2 hours prior to ECT
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31163978

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily
Number of subjects: 27935

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice daily alone
Number of subjects: 27935

Group type: COMPARATOR
Intervention: Aspirin 100 mg alone
Number of subjects: 27935

Group type: EXPERIMENTAL
Intervention: Rivaroxaban and aspirin
Number of subjects: 27935

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 27935
Study: 29983376

Group type: EXPERIMENTAL
Intervention: YESHealth intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27626518

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control (chemotherapy without rituximab)
Number of subjects: 209
Study: 24493237

Group type: EXPERIMENTAL
Intervention: REACH Forgiveness intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 102
Study: 21450591

Group type: EXPERIMENTAL
Intervention: RPE group (35 subjects)
Number of subjects: 71

Group type: COMPARATOR
Intervention: AeT group (36 subjects)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Percentage heart rate reserve and peak workload methods
Number of subjects: 71
Study: 20386260

Group type: EXPERIMENTAL
Intervention: STEPPS plus an adjunctive individual therapy
Number of subjects: 79

Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 79
Study: 18353631

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with chemotherapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Preoperative radiotherapy without chemotherapy
Number of subjects: 95
Study: 15994714

Group type: EXPERIMENTAL
Intervention: Integrated care (tobacco use treatment delivered by mental health providers)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual standard of care (cessation treatment delivered separately by smoking‐cessation specialists)
Number of subjects: 66
Study: 12623832

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol combination
Number of subjects: 293

Group type: COMPARATOR
Intervention: Brimonidine + timolol
Number of subjects: 293
Study: 10100063

Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine 10-40 mg/day)
Number of subjects: 3506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3506
Study: 8904620

Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 1725033

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg/day (treatment A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ramipril 1.25 mg/day (treatment B)
Number of subjects: 16
Study: 6350409

Group type: EXPERIMENTAL
Intervention: Intranasal aspirin (ASA) 22.5 mg per deciliter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal aspirin (ASA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of ASA, Na salicylate, and indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 31448718

Group type: EXPERIMENTAL
Intervention: BRP varnish 2.5%
Number of subjects: 24
Study: 31329961

Group type: EXPERIMENTAL
Intervention: 10-minute mindfulness strategy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison group (education on the Gate Control Theory of Pain)
Number of subjects: 60
Study: 28611080

Group type: EXPERIMENTAL
Intervention: MRI-assessed inflammation
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: MRI-assessed synovitis
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: MRI-assessed synovitis and tenosynovitis mean scores
Number of subjects: 210
Study: 27756209

Group type: EXPERIMENTAL
Intervention: mDOT (mobile directly observed therapy) with fixed dose hydroxyurea (HU) therapy and standard monitoring
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard monitoring (SM) with fixed dose hydroxyurea (HU) therapy
Number of subjects: 100
Study: 25144885

Group type: EXPERIMENTAL
Intervention: Dynamic abduction brace with Mitchell shoes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Static abduction bar with Mitchell shoes
Number of subjects: 30